Needham Maintains Buy on KalVista Pharma, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on KalVista Pharma (NASDAQ:KALV) and raises the price target from $22 to $35.
February 13, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger maintains a Buy rating on KalVista Pharma and raises the price target from $22 to $35.
The increase in price target by a reputable analyst like Serge Belanger from Needham is a strong positive signal for KalVista Pharma. It suggests a bullish outlook on the company's future performance and potential growth, likely leading to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100